AlphAIAlphAI — Financial news for AI agents
tradingview.com$ASIX

AdvanSix (ASIX) Q3 Sales Rose 15%, Adjusted EBITDA Fell $10.1M

AdvanSix reported Q3 2026 sales up 15% YoY to $431M, but adjusted EBITDA fell $10.1M to $14.6M and adjusted EPS declined $0.32 to -$0.24. Operating cash flow increased $21.4M to $48.0M. The company cited production and input-cost pressures.

Original reporting
tradingview.com
Published Nov 4, 2026, 11:30 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 4, 2026, 11:40 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AdvanSix (ASIX) Q3 Sales Rose 15%, Adjusted EBITDA Fell $10.1M — source image
Source · tradingview.com
Decision brief

The 30-second read

$ASIXBearishMed
01

Why it matters

The mixed results suggest a near‑term pullback but leave room for upside if cost efficiencies materialize.

02

Market read

Earnings release provides fresh data for traders; the EBITDA miss may trigger short‑term selling pressure.

03

What to watch

Cost‑absorption improvements and cash‑flow increase may mitigate earnings weakness.

Relevance 7/10Novelty 7/10Timing: post‑market today

Background

AdvanSix released its Q3 2026 earnings via BusinessWire, highlighting pricing‑driven sales growth and input‑cost pressures.

Company-level read

Ticker impact

$ASIXBearishHigh confidence
Context

Q3 2026 sales rose 15% YoY to $431M but adjusted EBITDA fell $10.1M to $14.6M, indicating weaker earnings despite revenue growth.

Expected impact

likely downside as market prices in weaker profitability

Evidence & confidence

Revenue growth is offset by a significant EBITDA decline, suggesting margin pressure and potential cash‑flow concerns.

Market effects

Sector

Chemicals sector may see broader scrutiny on margin trends.

Regional

U.S. industrial stocks could face modest pressure.

Global

Limited to investors tracking mid‑cap chemical manufacturers.

Counterpoint

What could challenge this read

Revenue beat could support a short‑term rally if investors focus on top‑line growth.

Key entities

  • Company
    AdvanSix

    U.S. specialty chemicals manufacturer reporting Q3 2026 results.

Read at source← All news

StoryAdvanSix Reports Q3 Loss as Sales Rise but Adjusted EBITDA Declines

Also covered by

3 outlets

Related articles

Med

AdvanSix Inc. Q3 2026 Earnings Call Summary

AdvanSix Inc. reported Q3 2026 earnings, highlighting 17% favorable pricing offsetting $65M raw material cost increases. The company maintained high operating rates, optimized production, and reduced fixed costs. It expects Q4 price-over-raws headwinds and a 2027 ammonium sulfate supply shortage. AdvanSix secured a $47M USDA grant for Project CENTURY and closed a $425M credit facility.

finance.yahoo.com
$ASIXMedAI 8/10

AdvanSix (ASIX) Q3 2026 Earnings Call Transcript

AdvanSix (ASIX) reported Q3 2026 sales of $431M, up 15% YoY, driven by pricing. Adjusted EBITDA was $15M, down $10M YoY. Ammonia sales expected to rise 25% for the year. Nylon resin production up 5% YoY. Company focuses on cost reduction, operational excellence, and disciplined capital deployment.

finance.yahoo.com
$ASIXHigh

AdvanSix stock slips 2% on third quarter earnings miss

AdvanSix Inc. (ASIX) reported Q3 earnings that missed expectations, with an adjusted loss per share of -$0.24 vs. $0.28 estimate. Revenue was $430.81M, up 15% YoY. Stock fell 2% in pre-market trading. The company cited strong commercial execution and pricing strategies to offset inflation. Adjusted EBITDA declined to $14.6M, while cash flow improved to $48M. ASIX refinanced its credit facility and declared a $0.16 quarterly dividend.

investing.com